Other
Eli Lilly’s (LLY) retatrutide delivered greater A1C reduction and more than double the weight loss of Novo Nordisk’s (NOVOB DC) Ozempic at its highest approved dose in head-to-head trial
ORIGINAL · NewsquawkEli Lilly’s (LLY) retatrutide delivered greater A1C reduction and more than double the weight loss of Novo Nordisk’s (NOVOB DC) Ozempic at its highest approved dose in head-to-head trial
StockNow breaking-news AI analysis
The headline reports greater A1C reduction and more than double the weight loss with retatrutide versus highest-dose Ozempic; trial details and numerical results are unavailable.
Related stocks
2 stocks
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.